Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension

Model scores of the 29,894 trials active now.

Model score 14% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (493 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2009-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: evidenceheartsubjectscoronaryrandomization
  Phrases that lowered it: and safetyefficacy andsafety ofthe efficacyclinical trial
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Responsible party: not given (raises risk) · Design
• Sponsor's past termination rate: 6.9% (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 7.2% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Number of arms: 4 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 23 (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 47005 (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 74.8% (lowers risk) · Drug's FDA history
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 12394 (lowers risk) · Drug's FDA history
• Blinding: double (raises risk) · Design
• Keywords listed: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension NCT00923091 · started 2009 · scored riskier than 20% of active trials completed
• Irbesartan and Amlodipine Combination in Controlling Blood Pressure NCT00950066 · started 2009 · scored riskier than 17% of active trials completed
• Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension NCT00902538 · started 2009 · scored riskier than 10% of active trials completed
• Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension NCT00699192 · started 2008 · scored riskier than 28% of active trials completed
• A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy NCT02368652 · started 2014 · scored riskier than 12% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.